-
Baiji Shenzhou: Net loss of 3.878 billion yuan in the first three quarters
Baekje Shenzhou: Net Loss of 3.878 billion yuan in the First Three Quarters: Baekje Shenzhou disclosed its third quarter report, with a net profit of 1.34 billion yuan in the third quarter and a net ... -
Baiji Shenzhou Small Molecular Innovative Drug Global Industrialization Base Launched in Suzhou
Shanghai Securities News China Securities Network News (Reporter Zhang Xue): The reporter learned from Baekje Shenzhou that on November 16th, the Baekje Shenzhou Small Molecule Innovative Drug Global ... -
Baekje Shenzhou Introduces Onsen Pharmaceuticals CDK2 Inhibitors for $1.33 billion
On November 21st, Baekje announced that it had reached a cooperation agreement with Ensem Therapeutics to introduce the CDK2 inhibitor ETX-197, which the latter is about to submit for IND (drug clini ... -
Hong Kong stock Baekje Shenzhou rose by nearly 5% in late trading
On the afternoon of December 27th, the Hong Kong stock of Baekje Shenzhou rose by nearly 5% in late trading. -
New indications for BeiGene PD-1 inhibitor for first-line treatment of hepatocellular carcinoma
On January 2, 2024, Baekje Shenzhou announced its PD-1 inhibitor Baekzeon& Reg; The new indication of (tirizizumab) has been approved by the National Medical Products Administration (NMPA) of China f ... -
Baekje Shenzhou fined 400000 yuan for illegal promotion of prescription drugs
According to Tianyancha, BeiGene (Shanghai) Biotechnology Co., Ltd. was fined 400000 yuan by the Jing'an District Market Supervision Administration for promoting prescription drugs in violation of re ... -
Baekje Shenzhou fined 400000 yuan for placing prescription drug Yilapao advertisements in the venue
A recent "Administrative Penalty Decision" released by the Market Supervision Administration of Jing'an District, Shanghai has attracted attention. Due to illegal advertising of prescription drugs th ... -
BeiGene: Dr. Olivier Brandicourt appointed as an independent non-executive director of the board of directors
Baekje Shenzhou (SH 688235, closing price: 122.8 yuan) announced on the evening of January 23 that Mr. Thomas Malley resigned from his position as an independent non-executive director and correspond ... -
Baekje Shenzhou releases its 2023 performance report. Zebtinib's global sales in 2023 exceeded the $1 billion mark
On the evening of February 26th, Baekje Shenzhou released its 2023 A-share performance report, stating that Zebtinib's global sales in 2023 have exceeded the $1 billion mark. In 2023, the company's a ... -
Baekje Shenzhou Zebtinib's global revenue exceeded one billion US dollars for the first time in 2023
On February 26th, BeiGene (NASDAQ code: BGNE; Hong Kong Stock Exchange code: 06160.HK; Shanghai Stock Exchange code: 688235. SH) released its 2023 fourth quarter and full year US stock performance re ... -
In 2023, BeiGene's product revenue reached 15.504 billion yuan, and Zebtinib's global sales exceeded 1 billion US dollars
On February 26th, BeiGene released its 2023 A-share performance report. According to the announcement, in 2023, BeiGene's product revenue was 15.504 billion yuan, compared to 8.48 billion yuan in the ... -
Baekje Shenzhou Baiyue Ze has received FDA accelerated approval for the treatment of recurrent or refractory follicular lymphoma
Recently, BeiGene announced that Baiyue Ze& Reg; Zebutinib has been granted accelerated approval by the US Food and Drug Administration (FDA) for use in combination with the anti-CD20 monoclonal anti ... -
BeiGene: The first indication approved for tirizizumab in the United States
On March 15th, Baekje announced that the US Food and Drug Administration (FDA) has approved tirizizumab (Chinese trade name: Baekzean®; English trade name: TEVIMBRA®) as a monotherapy for adu ... -
Baekje Shenzhou PD-1 has been approved by FDA as the second product in China after Junshi Biotechnology
Beijing, March 15th (Reporter Cao Qian, Intern Xie Xiaoxuan) Today, BeiGene announced that its PD-1 inhibitor, Tevimbra, has been approved by the FDA for the treatment of advanced or metastatic esoph ... -
After a series of twists and turns, the core product of Baekje Shenzhou, Baekze An, has become the second domestically produced PD-1 approved in the United States
After nearly two years, the BeiGene PD-1 has finally knocked on the door of the US FDA. On March 15th, Baekje Shenzhou announced that the FDA has approved the Baekje Shenzhou PD-1 inhibitor tirelizum ... -
BeiGene: Net profit for 2023 is approximately -6.716 billion yuan
Baekje Shenzhou (SH 688235, closing price: 130.77 yuan) released its annual performance report on April 27, stating that its operating revenue in 2023 was approximately 17.423 billion yuan, an increa ... -
BeiGene: Chief Financial Officer Wang Aijun will resign on July 19th
According to AI News, on July 18th, BeiGene announced that its Chief Financial Officer, Wang Aijun, has recently submitted a resignation application to seek external development opportunities. He wil ... -
Company Review | BeiGene has suffered continuous losses in the past 7 years, and its stock price is under pressure. Can the new CFO bring a turning point?
On August 7th, BeiGene (SH688235, stock price 140.88 yuan, market value 193.9 billion yuan) released its financial report for the first half of 2024, with a total operating revenue of 11.996 billion ... -
More than 40% reduction in losses in the first half of the year, but multiple peers have achieved profits. BeiGene is facing increasing peer pressure
In the first half of the year, BeiGene (688235.SH, stock price 145.48 yuan, market value 2002.31 billion yuan) has been the "leader" in China's new drug industry for more than 2 years, but has not ye ... -
AbbVie sues for infringement again, BeiGene denies allegations: this move is intended to prevent project development
Two companies in the field of hematological oncology, AbbVie and BeiGene, have once again taken legal action. Industry media Fierce Biotech recently reported that AbbVie has filed a lawsuit against B ...